EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

From Failure to Success: Evaluating Infliximab Efficacy After Adalimumab Failure in Hidradenitis Suppurativa

R. Srour, J. Shapiro, E. Avitan-Hersh, R. Kassem, B. Jiryis, N. Bathish, Z. Khamaysi

Dermatologic Therapy · 2026-01 · 2026 (1)

DOI: 10.1155/dth/9020978 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 29.06.2026. Verfasst von R. Srour und 6 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hidradenitis suppurativa (HS) is a debilitating, chronic skin disease. Although adalimumab is a Food and Drug Administration (FDA)–approved biologic drug to treat HS, a significant number of patients develop primary or secondary failure to this treatment. Limited data exist in the literature on the effectiveness of the infliximab medication in such a group of patients. This study assesses the effectiveness and safety of infliximab treatment in patients diagnosed with HS whose adalimumab therapy has failed.

Methods

The current retrospective study collected data from medical records of 40 HS patients who received infliximab after failure of adalimumab. The parameters included an evaluation of hidradenitis suppurativa clinical response (HiSCR) and Dermatology Life Quality Index (DLQI) over time and determination of prognostic factors associated with the clinical response.

Results

Twenty‐nine of 40 patients (72.5%) who were administered infliximab reached HiSCR at 24 weeks, and 86.2% of them (25/29) persisted at 48 weeks. DLQI scores demonstrated that the impaired quality of life affecting the patients was improved significantly. The DLQI at baseline (mean 19.55 ± 4.4 [range 9–26]) has decreased by 24 weeks (mean 12.4 ± 5.08 [range 4–24]; p < 0.001) and 48 weeks (mean 11.8 ± 5.87 [range 2–25]; p < 0.001). Obesity (body mass index > 30), smoking, hypertension, disease duration, and primary adalimumab failure were negatively associated with HiSCR achievement and DLQI improvement. Adverse events were in line with the drug’s known safety profile.

Conclusion

Infliximab showed significant clinical efficacy in adalimumab‐unresponsive HS patients. Initiation of treatment at an early stage and management of modifiable risk factors like obesity and smoking can maximize the outcomes. These findings provide evidence to endorse the use of infliximab as an effective alternative treatment for HS after failure with adalimumab.

Zitieren

APA

Srour, R., Shapiro, J., Avitan-Hersh, E., Kassem, R., Jiryis, B., Bathish, N., & Khamaysi, Z. (2026). From Failure to Success: Evaluating Infliximab Efficacy After Adalimumab Failure in Hidradenitis Suppurativa. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/9020978

Vancouver

Srour R, Shapiro J, Avitan-Hersh E, Kassem R, Jiryis B, Bathish N, et al. From Failure to Success: Evaluating Infliximab Efficacy After Adalimumab Failure in Hidradenitis Suppurativa. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/9020978

BibTeX
@article{Srour2026,
  author = {Srour, R. and Shapiro, J. and Avitan-Hersh, E. and Kassem, R. and Jiryis, B. and Bathish, N. and Khamaysi, Z.},
  title = {From Failure to Success: Evaluating Infliximab Efficacy After Adalimumab Failure in Hidradenitis Suppurativa},
  journal = {Dermatologic Therapy},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/dth/9020978}
}
Kostenlos starten →